A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

Summary

PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine \[A549 Cells\], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.

Timeline

Start

2017-05-01

Primary completion

2017-11-27

Completion

2017-11-27

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Publications

• Beaty S, Collins N, Karasavvas N, Kuschner R, Hang J, Adhikari A, Maljkovic Berry I, Fung C, Walls S, Betancourt E, Mendy J, Lock M, Gierman E, Bennett S, Shabram P, Warfield K. A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults. Vaccines (Basel). 2023 Jun 12;11(6):1091. doi: 10.3390/vaccines11061091.

Drugs

Indications